What are ground glass nodules in the lungs?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 27, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ground Glass Nodules in the Lungs: Definition and Clinical Significance

Ground glass nodules (GGNs) are focal, rounded opacities in the lungs that appear hazy on CT scans, often representing early-stage lung adenocarcinoma or its precursor lesions, requiring careful monitoring and management based on their size, appearance, and growth pattern. 1

Definition and Radiological Characteristics

  • GGNs are focal opacities on CT imaging that appear as hazy increases in lung density without obscuring underlying bronchial and vascular structures 1
  • They are categorized into two main types:
    • Pure ground-glass nodules (pGGNs): Entirely hazy appearance without solid components 1
    • Part-solid nodules (PSNs): Contain both ground-glass and solid components 1
  • GGNs are best evaluated using lung window settings with an edge-enhancing (sharp) filter to accurately assess the presence and extent of solid components 1

Pathological Correlation

GGNs correlate with specific pathological entities based on their appearance:

  • Pure ground-glass nodules (pGGNs):

    • Small pGGNs (<5 mm): Often represent atypical adenomatous hyperplasia (AAH), a premalignant lesion 1
    • Larger pGGNs (>5 mm up to 30 mm): Frequently adenocarcinoma in situ (AIS), a preinvasive lesion 1
  • Part-solid nodules (PSNs):

    • PSNs with solid component <5 mm: Typically minimally invasive adenocarcinoma (MIA) 1
    • PSNs with larger solid components or solid nodules: Usually invasive adenocarcinoma 1

Clinical Significance and Malignancy Risk

  • The presence of a solid component within a GGN is the strongest predictor of growth and malignancy 1, 2
  • Approximately 20% of pure GGNs and 40% of part-solid GGNs will gradually grow or increase their solid components over time 3
  • A solid component larger than 5 mm correlates with a substantial likelihood of local invasion 1
  • Most persistent or growing GGNs represent lung adenocarcinomas or their preinvasive lesions 3

Management Approach

Management depends on nodule characteristics:

  • For pure ground-glass nodules:

    • <6 mm: No routine follow-up needed in low-risk patients; optional CT at 2 and 4 years in high-risk patients 1
    • ≥6 mm: CT follow-up at 6-12 months to confirm persistence, then every 2 years for at least 5 years 1, 3
  • For part-solid nodules:

    • <6 mm: No routine follow-up needed in low-risk patients; optional CT at 2 and 4 years in high-risk patients 1
    • ≥6 mm with solid component <6 mm: CT follow-up at 3-6 months to confirm persistence, then annual follow-up for 5 years 1
    • ≥6 mm with solid component ≥6 mm: Consider short-term CT follow-up, PET/CT, biopsy, or resection 1

Important Considerations and Pitfalls

  • GGNs require longer follow-up periods (at least 5 years) compared to solid nodules due to their typically indolent growth 3
  • Interobserver agreement on classifying nodules as solid, part-solid, or pure ground-glass is highly variable, with correct classification by all radiologists achieved in only 58% of cases 1
  • Multiple GGNs may represent multifocal primary adenocarcinoma rather than metastatic disease 1
  • While lobectomy remains the standard surgical procedure for lung cancer, limited surgery (wedge resection or segmentectomy) may be appropriate for small GGN-associated cancers with limited solid components 3, 4
  • Smoking history and lesion size are important predictors of GGN growth, with EGFR mutations also potentially predicting growth 3

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.